Frontiers in Oncology | |
Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma | |
Oncology | |
Shuqi Xie1  Fanming Kong1  Yan Ou1  Mengchao Wang1  Dong Wang1  Dan Yi1  Chuanxiu Zeng1  Liwei Chen1  Lu Zhao1  | |
[1] Department of Oncology, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China; | |
关键词: targeted therapy; immunotherapy; research progress; hepatocellular carcinoma; combination therapy; | |
DOI : 10.3389/fonc.2023.1197698 | |
received in 2023-03-31, accepted in 2023-05-16, 发布年份 2023 | |
来源: Frontiers | |
【 摘 要 】
Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications, significantly prolonging patient survival. This paper reviews the research progress of molecular-targeted drugs combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma and discusses the effectiveness and safety of the combination of the two drugs to provide a reference for the further application of molecular-targeted drugs combined with immune checkpoint inhibitors in clinical practice.
【 授权许可】
Unknown
Copyright © 2023 Xie, Wang, Zeng, Ou, Zhao, Wang, Chen, Kong and Yi
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310106003192ZK.pdf | 866KB | download |